Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acyclovir in chronic hepatitis B virus infection.

A P Fiddian

    Scandinavian Journal of Infectious Diseases. Supplementum
    |January 1, 1985
    PubMed
    Summary

    New antiviral agents, like acyclovir, show promise for chronic hepatitis B treatment. Further controlled trials are needed to determine the effectiveness of oral acyclovir prodrugs in managing this public health concern.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Antiviral developments.

    Reviews in medical virology·2000
    Same author

    Antiviral developments. Three new drugs approved for treatment of HIV infection.

    Reviews in medical virology·1999
    Same author

    European CPMP gives positive opinion on lamivudine for chronic hepatitis B.

    Reviews in medical virology·1999
    Same author

    Treatment of acute herpes zoster: effect of early (< 48 h) versus late (48-72 h) therapy with acyclovir and valaciclovir on prolonged pain.

    The Journal of infectious diseases·1998
    Same author

    Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data.

    The Journal of infectious diseases·1998
    Same author

    A randomized controlled trial of acyclovir versus netivudine for treatment of herpes zoster. International Zoster Study Group.

    The Journal of antimicrobial chemotherapy·1998

    Area of Science:

    • Hepatology
    • Virology
    • Pharmacology

    Background:

    • Chronic hepatitis B is a significant global public health issue.
    • Limited effective therapies and screening methods necessitate empirical treatment approaches.
    • Acyclovir has emerged as a potential antiviral agent for hepatitis B.

    Purpose of the Study:

    • To review the current status of empirical antiviral therapies for chronic hepatitis B.
    • To evaluate the potential role of acyclovir and its derivatives in managing hepatitis B.
    • To highlight the need for controlled clinical trials to establish treatment efficacy.

    Main Methods:

    • Review of existing studies on antiviral agents for chronic hepatitis B.
    • Analysis of clinical data regarding acyclovir's efficacy and tolerability.
    • Discussion of the development and potential of acyclovir prodrugs for oral administration.

    Main Results:

    • Several antiviral agents, including acyclovir, have shown some success in preliminary studies.
    • Acyclovir is well-tolerated but currently requires intravenous administration.
    • New acyclovir prodrugs may allow for oral administration, expanding treatment options.

    Conclusions:

    • Empirical antiviral therapy is being explored due to the limitations in treating chronic hepatitis B.
    • Acyclovir demonstrates potential, but its role requires validation through controlled trials.
    • The ultimate utility of oral acyclovir prodrugs in single or combination therapy for chronic hepatitis B is yet to be established.

    Related Experiment Videos